Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eslicarbazepine acetate + ethinylestradiol + levonorgestrel
- Development stage
- Unknown
- Lead developer
- Bial
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to the co-administration of eslicarbazepine acetate (BIA 2-093) and a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. Eslicarbazepine acetate is a small molecule voltage-gated sodium channel blocker developed by Bial - Portela C S.A. for the treatment of partial-onset seizures in patients with epilepsy. It acts by stabilizing the inactivated state of voltage-gated sodium channels, thereby preventing repetitive neuronal firing. The combination was evaluated in clinical trials (such as NCT00898560) to assess the impact of eslicarbazepine acetate on the pharmacokinetics of hormonal contraceptives. Eslicarbazepine acetate is a weak inducer of the CYP3A4 enzyme, which can lead to increased metabolism and reduced plasma concentrations of ethinylestradiol and levonorgestrel, potentially compromising contraceptive efficacy in women with epilepsy.
- Brand names
- AptiomZebinixMicroginon
- Other names
- eslicarbazepine acetateethinylestradiollevonorgestrelcombined oral contraceptive
02
Targets
CaV3 (Caveolin-3)PR (Progesterone receptor)ER (Estrogen receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on eslicarbazepine acetate + ethinylestradiol + levonorgestrel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eslicarbazepine acetate + ethinylestradiol + levonorgestrel.